Drug Name:
SERNIVO Rx
Generic Name and Formulations:
Betamethasone (as dipropionate) 0.05%; spray.
Company:
Promius Pharma, LLC
Therapeutic Use:
Indications for SERNIVO:
Mild-to-moderate plaque psoriasis.
Adult:
≥18yrs: apply to affected areas twice daily for up to max 4 weeks; discontinue when control is achieved. Do not occlude.
Children:
<18yrs: not recommended.
Warnings/Precautions:
Not for oral, ophthalmic, or intravaginal use. Systemic absorption increased by altered skin barrier, inflamed skin, prolonged use, application to large surface area, or use of occlusive dressings. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, hyperglycemia, glucosuria, or irritation occurs. Do not use on face, axillae, or groin, or if atrophy is present at treatment site. Allergic contact dermatitis. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Pharmacological Class:
Corticosteroid.
Adverse Reactions:
Pruritus, burning, stinging, pain, atrophy, telangiectasia, dermatitis, discoloration, folliculitis, skin rash; HPA axis suppression (esp. in children).
Generic Availability:
NO
How Supplied:
Spray—60mL, 120mL
Neurology Advisor Articles
- The Consequences of Compensation in Autism
- Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy
- Novel Therapy May Improve Symptoms in Early Huntington Disease
- Interaction of Alcohol, Smoking on Multiple Sclerosis Severity
- Are Vaccines Associated With Multiple Sclerosis Relapse?
- The Symbiosis of Headache and Sleep
- Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy
- Neurosurgery in Parkinson Disease: A Brief History and Look Forward
- Blood Pressure-Dementia Link May Be Affected by Population Characteristics
- The Consequences of Compensation in Autism
- Pain, Psychiatric Comorbidities More Common in Chronic vs Episodic Migraine
- Adjunctive Eslicarbazepine Safe and Well Tolerated for Pediatric Seizures
- Erenumab Shown to Reduce Headache Days for Patients with Episodic Migraine
- New Zolmitriptan Intracutaneous System Safe and Effective for Migraine
- DBS Improves Inpatient Outcomes for Comorbid Parkinson Disease and Depression